Ethics code: IR.TMI.RCE.1398.014
Abstract: (22 Views)
A B S T R A C T
Background and Objectives
Graft-versus-host disease (GvHD) remains a major complication of hematopoietic stem cell transplantation (HSCT), significantly affecting patient survival quality of life, and overall treatment outcomes. This study aimed to provide a comprehensive review of strategies for reducing GvHD in murine models, with a specific focus on the role of hematopoietic stem cells and the underlying immune system mechanisms.
Materials and Methods
This review study was conducted through a literature search in PubMed, Scopus, and Web of Science databases for articles pubished between 2000 and 2025. From 1,200 initial records, 155 articles met the inclusion criteria after screening, of which 55 studies were ultimately selected for final analysis. The included studies primarily investigated pharmacological interventions, monoclonal antibodies, signaling pathway inhibitors, and cellular therapies.
Results
The findings indicated that several therapeutics strategies reduced the incidence and severity of GvHD in murine models. These included pharmacological agents such as cyclosporine and azacitidine, monoclonal antibodies such as tocilizumab, signaling pathway inhibitors particularly targeting JAK/STAT, and cellular approaches involving regulatory T cells (T regs) and mesenchymal stem cells (MSCs). Notably, recent research has demonstrated the efficacy of MSC in treating various diseases’ and the regulatory role of JAK inhibitors in controlling GvHD. In many studies, the graft-versus-tumor (GVT) effect was largely preserved, highlighting the need for balanced and targeted therapeutic strategies.
Conclusions
This rewiew demonstrated that immunodeficient murine models remain valuable tools for investigating GvHD pathophysiology and evaluating novel therapeutic approaches. The use of innovative immunotherapeutic strategies, modulation of inflammatory responses, and the application of regulatory cells may play a significant role in reducing the severity of GvHD. The implementation of combination approaches, selection of interventions tailored to the patient’s condition, and personalization of treatment may help establish a balance between controlling GvHD and preserving the graft-versus-tumor effect. However, differences between murine models and human clinical conditions remain a major obstacle to translating these findings into therapeutic practice. Therefore, further studies are necessary to determine safety, efficacy, and optimal timing and dosage of treatment.
Background and Objectives
Graft-versus-host disease (GvHD) remains a major complication of hematopoietic stem cell transplantation (HSCT), significantly affecting patient survival quality of life, and overall treatment outcomes. This study aimed to provide a comprehensive review of strategies for reducing GvHD in murine models, with a specific focus on the role of hematopoietic stem cells and the underlying immune system mechanisms.
Materials and Methods
This review study was conducted through a literature search in PubMed, Scopus, and Web of Science databases for articles pubished between 2000 and 2025. From 1,200 initial records, 155 articles met the inclusion criteria after screening, of which 55 studies were ultimately selected for final analysis. The included studies primarily investigated pharmacological interventions, monoclonal antibodies, signaling pathway inhibitors, and cellular therapies.
Results
The findings indicated that several therapeutics strategies reduced the incidence and severity of GvHD in murine models. These included pharmacological agents such as cyclosporine and azacitidine, monoclonal antibodies such as tocilizumab, signaling pathway inhibitors particularly targeting JAK/STAT, and cellular approaches involving regulatory T cells (T regs) and mesenchymal stem cells (MSCs). Notably, recent research has demonstrated the efficacy of MSC in treating various diseases’ and the regulatory role of JAK inhibitors in controlling GvHD. In many studies, the graft-versus-tumor (GVT) effect was largely preserved, highlighting the need for balanced and targeted therapeutic strategies.
Conclusions
This rewiew demonstrated that immunodeficient murine models remain valuable tools for investigating GvHD pathophysiology and evaluating novel therapeutic approaches. The use of innovative immunotherapeutic strategies, modulation of inflammatory responses, and the application of regulatory cells may play a significant role in reducing the severity of GvHD. The implementation of combination approaches, selection of interventions tailored to the patient’s condition, and personalization of treatment may help establish a balance between controlling GvHD and preserving the graft-versus-tumor effect. However, differences between murine models and human clinical conditions remain a major obstacle to translating these findings into therapeutic practice. Therefore, further studies are necessary to determine safety, efficacy, and optimal timing and dosage of treatment.
Type of Study: Review Article |
Subject:
Hematology and Oncology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
